2. WHAT IS IRRITABLE BOWEL SYNDROME
irritable bowel syndrome can be defined
,as an idiopathic clinical entity characterized by
chronic(more than 3months)abdominal pain or discomfort
that occurs in association with altered bowel habits
Most are due to disorders of intestinal motility.
3. SYMPTOMS
These symptoms may be continuous or intermittent.
Consensus definition of irritable bowel syndrome is
abdominal discomfort or pain that has two of the
following three features;
1.Relieved with defecation.
2.Onset associated with a change in frequency
of stool
3.onset associated with a change in form of
stool
.
4. Other symptoms supporting the diagnosis include
abnormal stool frequency;
abnormal stool form (lumpy or hard;loose or watery);
abnormal stool passage (straining, urgency,or feeling of
abdominal distention
6. PATHO -PHYSIOLOGY OF IBS
SUGGETSED THEORIES
1.Altered responses of general stress circuits.
2.The alternation of autonomic and
neuroendocrine systems in response to visceral
stimulation.
3. Serotonin release
4.low grade inflammation
5. IBS secondary to GIT
infections
10. TREATMENT
FOOD INTOLERANCE TRY EXCLUSION DIET
CONSTIPATION
1. INCREASE FIBER UPTAKE
2. BULK PURGATIVES
ISPAGHULA AND PSYLLIUM
NATURAL COLLOIDAL MUCILAGE FORMS GELATINOUS MASS
BY ABSORBING WATER
3-12 g OF HUSK IS MIXED WITH WATER OR MILK
TAKEN DAILY ACT IN 1- 3 DAYS
11. METHYLCELLULOSE
SEMISYNTHETIC COLLOIDAL HYDROPHILIC DERIVATIVE OF
CELLULOSE
4-6 g/day
They have non fermentable fiber better than lactulose which ferments
3 .ANTHRAQUINONES
TEGASEROD
NEW SELECTIVE 5 – HT4 RECEPTOR PARTIAL AGONIST WITH NO
ACTION ON OTHER RECEPTORS
IT ENHANCES RELEASE OF Ach AND calcitonin GENE RELATED
PEPTIDE WHICH PROMOTE PERISTALTIC REFLEX AND COLONIC
SECRETION
elimination t1/2 of absorbed drug 11 hr
13. DIARRHOEA
1. Bulking agent
as absorbants ispaghula and other bulk forming colloid are
useful in both constipation and diarrhoea .
They modify the consistency and frequency of stools by
absorbing water
14. ANTISECRETORY
SULFASALAZINE
compound of 5-aminosalicylic acid with sulfapyridine linked
through azo bond.
5-ASA it inhibits COX and LOX ,decreased PG and LT, they play
minor role in the therapeutic effect.
Inhibition of cytokine, PAF, TNF and nuclear transcription factor
Migration of inflammatory cells into bowel wall is interfered and
mucosal secretion is reduced
15. DOSE -3-4 g/day induces remission over a few
weeks but relapses are common after stoppage
Maintenance therapy with 1.5-2 g/day postpone
relapse
Adverse effects
Rashes ,fever, joint pain, hemolysis
16. MESALAZINE
formulated as delayed release preparation by
coating of 5-ASA with acrylic polymer
This helps in effective delivery of the drug
DOSE - 2.4 gm prevents relapses
adverse effects are less than sulfasalazine
17. OTHER FORMS – 5 ASA enemas
Olsalazine
Balsalazine
Other drugs helpful
Corticosteroids
Immunosuppressants
Antispasmodic in colic and bloating
18. Antimotility drug
(opoid drugs codiene , diphenoxylate , loperamide )
Contraindicated as they increase the intraluminal pressure